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Protein restriction and AST-120 improve lipoprotein lipase
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Protein restriction and AST-120 improve lipoprotein lipase
and VLDL receptor in focal glomerulosclerosis.
Background. Imai rats exhibit spontaneous focal glomerulo-
sclerosis (FGS) with progressive proteinuria and hyperlipid-
emia leading to renal insufficiency by age 34 weeks. Recently,
we reported marked down-regulations of skeletal muscle and
adipose tissue lipoprotein lipase (LPL) and very low-density
lipoprotein (VLDL) receptor in male Imai rats at 32 weeks of
age. Dietary protein restriction and oral adsorbent AST-120
(AST) have been shown to slow progression of renal disease
and attenuate hyperlipidemia in the Imai rats. This study tested
the hypothesis that amelioration of proteinuria by protein re-
striction or use of oral adsorbent AST-120 beginning at 10
weeks of age may improve renal disease and LPL and VLDL
receptor deficiencies in Imai rats.
Methods. Ten-week-old male Imai rats were randomly as-
signed to those fed either a regular diet, low protein diet (LPD),
or regular diet containing the adsorbent preparation, AST-120.
Ten-week-old male Sprague-Dawley rats served as controls.
The animals were observed for 24 weeks. Six rats were included
in each group. All diets were prepared in powder form.
Results. The untreated 34-week-old Imai rats showed severe
proteinuria, hypoalbuminemia, 50% reduction in creatinine
clearance, hypercholesterolemia, hypertriglyceridemia, and el-
evated plasma VLDL concentration. This was associated with
significant reductions in plasma post-heparin LPL activity, he-
patic lipase activity, as well as adipose tissue and skeletal muscle
immunodetectable LPL and VLDL receptor proteins. Protein
restriction mitigated the decline in creatinine clearance, amel-
iorated proteinuria, hypoalbuminemia, hypertension, and hy-
percholesterolemia, lowered plasma VLDL, and improved
plasma postheparin LPL activity, hepatic lipase activity, LPL,
and VLDL receptor proteins in skeletal muscle and adipose
tissue. Similar improvements were observed in all parameters
with AST administration.
Conclusion. Moderate protein restriction and use of oral
adsorbent can slow progression of renal disease and, thereby,
ameliorate LPL, hepatic lipase, and VLDL receptor deficienc-
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ies and the associated hyperlipidemia in rats with spontane-
ous FGS.
Imai rats exhibit a progressive focal glomerulosclerosis
(FGS) presenting with proteinuria and hyperlipidemia
beginning at 8 to 10 weeks of age leading to renal insuffi-
ciency and death by 30 to 36 weeks of age [1, 2]. In a
series of earlier studies intended to discern the molecular
mechanisms of dyslipidemia in this model, we found
marked down-regulation of skeletal muscle and adipose
tissue lipoprotein lipase (LPL) and very low-density lipo-
protein (VLDL) receptor expressions [3]. These findings
helped to elucidate the mechanism of hypertriglyceride-
mia, elevation of VLDL, and impaired clearance of
VLDL and chylomicrons in Imai rats with advanced
FGS. In a subsequent study, we found up-regulation of
hepatic 3-hydroxy-3-methylglutaryl coenzyme A (HMG-
CoA) reductase and acyl-CoA cholesterol acyl-trans-
ferase (ACAT-2) coupled with down-regulation of low-
density lipoprotein (LDL) receptor in this model [4].
Together, these abnormalities account for severe hyper-
cholesterolemia and elevation of LDL cholesterol con-
centration in Imai rats with advanced FGS [4]. Moreover,
the study revealed severe reduction of plasma leci-
thine:cholesterol acyltranferase (LCAT), which explains
impaired high-density lipoprotein (HDL) maturation in
these animals [4]. The latter has been shown to be due
to massive urinary losses of LCAT in nephrotic syn-
drome [5].
The plasma lipid profile in the young Imai rats prior
to onset of proteinuria (6 weeks of age) is nearly normal
and progressive hyperlipidemia occurs coincidentally
with the onset of proteinuria [1]. These observations
point to contributions of nephrotic proteinuria and sub-
sequent renal insufficiency to progressive dyslipidemia
in this model. In fact, up-regulation of HMG-CoA reduc-
tase and hepatic ACAT-2, as well as LCAT deficiency
and down-regulations of LPL, hepatic lipase, and VLDL
receptor in this model have been previously demon-
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strated in rats with puromycin-induced nephrotic syn-
drome [5–11]. The effect of nephrotic syndrome in this
model is compounded by the superimposed renal insuf-
ficiency, which has been shown to cause down-regulation
of LPL, VLDL receptor, and LCAT, as well as up-regula-
tion of hepatic ACAT-2 [12–16]. Dietary protein restric-
tion has been shown to reduce proteinuria in nephrotic
animals [17] and humans [18, 19]. In addition, oral admin-
istration of AST-120 (AST) (an activated charcoal prep-
aration) has been shown to slow progression of renal
insufficiency in rats with 5/6 nephrectomy [20], in Imai
rats with spontaneous FGS [21], as well as in humans
with advanced chronic renal failure [22].
In view of the above considerations, we hypothesize
that dietary protein restriction and administration of the
oral adsorbent, AST-120, may ameliorate hyperlipid-
emia and the underlying lipoprotein lipase, VLDL recep-
tor, and hepatic triglyceride lipase deficiencies in this
model by limiting proteinuria and retarding development
of renal insufficiency. The present study was undertaken
to test this hypothesis.
METHODS
Study groups
Imai rats used in the current study were bred and
raised in the animal facilities of Saga Medical School,
Saga, Japan. Ten-week-old male Imai rats were ran-
domly assigned to the three groups of untreated, low-
protein diet (LPD)–treated and oral adsorbent AST-
120–treated groups. Six animals were included in each
group. A group of male Sprague-Dawley rats served
as controls. Sprague-Dawley control rats and untreated
Imai rats were fed a standard rat chow (containing 24.8%
protein and 0.39% sodium chloride). The diet used in
the LPD group was a rat chow containing 12.4% protein
and 0.39% sodium chloride. The AST-treated group was
fed a regular rat chow to which AST-120 (Kureha Chemi-
cal Industry, Tokyo, Japan) was added at a dosage of
1.4 g/day/rat. All foods were prepared in powder form
and served in bowls placed inside the cages. The treat-
ments were initiated at 10 weeks of age and continued
for 24 weeks (age, 34 weeks).
All rats were permitted unrestricted access to food
and water and housed in individual cages. The LPD
necessarily contained more carbohydrate and, thus, rats
receiving this diet must have consumed proportionally
more carbohydrates than those consuming regular diet
with or without AST-120. Room temperature was main-
tained at 23C  2C, humidity was kept at 60%  10%
and a 12/12-hour light/dark cycle was employed. All pro-
cedures were reviewed and approved by the Saga Medi-
cal School’s Ethics Committee on Animal Experiments.
Twenty-four–hour urine specimens were collected at the
conclusion of the observation period. Food was withheld,
but water was provided during urine collections. Blood
was drawn from the tail artery immediately after the
urine collection to determine serum albumin, lipids, and
creatinine concentrations. At the conclusion of the 34-
week study period, arterial pressure was measured by
tail plethysmography. Thereafter, rats were killed by an
overdose of sodium pentobarbital, and adipose tissue (fat
pad) and skeletal muscle (soleus muscle) were harvested.
Tissues were immediately frozen in liquid nitrogen and
stored at 70C until being processed.
Post-heparin LPL and hepatic lipase activities
These measurements were carried out in separate sub-
groups at ages 20 and 34 weeks. To this end, blood was
collected in tubes containing ethylenediaminetetraace-
tate (EDTA) (1 mg/mL) 10 minutes after an intravenous
injection of heparin at 30 U/kg body weight. Plasma was
separated (by centrifuging the samples at 1500g for 15
minutes at 4C) and stored at70C until assayed. Serum
lipoprotein lipase and hepatic lipase activities were de-
termined using purified triolein as substrate. Briefly, an
emulsion was prepared from a mixture of 525 mol of
purified triolein, 4 mL of Triton X-100, 5 mL of 1 mol/L
Tris buffer (pH  8.5). and 8 mL of distilled water,
sonicated at 17 W for 3 minutes at 4C. The emulsion
was then supplemented with 10 mL of 10% bovine serum
albumin (BSA), 6 mL of 1 mol/L solution of sodium
chloride and 7 mL of normal human serum as a source
of apolipoprotein C-II (Apo C-II) required for activation
of LPL. Distilled water was then added to a final vol-
ume of 50 mL. This mixture was used as the substrate for
determination of serum LPL activity. Accordingly, 0.1
mL of the test sample was mixed with 1 mL of the above-
activated substrate at 37C for 60 minutes. The reaction
medium was then mixed with a mixture of petroleum
ether (85%) and ether (15%) and shaken for 15 minutes
followed by centrifugation at 3000 rpm for 10 minutes.
The amount of free fatty acids contained in the superna-
tant was then quantified by colorimetric analysis at 480
nm. Plasma post-heparin hepatic lipase activity was quan-
tified in a similar manner as described for LPL activity
except for the use of reaction substrate, which contained
a high sodium chloride concentration and was devoid
of Apo C-II. The substrate mixture for this assay was
prepared as described above except for deletion of nor-
mal serum (hence, Apo C-II) and addition of 13 mL of
3.85 mol/L sodium chloride instead of 6 mL of 1 mol/L
sodium chloride solution used for the LPL activity assay.
Plasma LPL and hepatic lipase activities in the test
samples were quantified from the rate of fatty acid re-
leased from hydrolysis of the substrate triolein. On each
occasion, plasma free fatty acid concentration was deter-
mined in a separate aliquot of plasma and the amounts
found were subtracted from that found following each
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Table 1. Serum concentrations of total cholesterol (T Chol), low-density lipoprotein (LDL), very low-density lipoprotein (VLDL),
and high-density lipoprotein (HDL) cholesterol, triglyceride (TG), VLDL triglyceride, albumin, and creatinine, creatinine
clearance, urinary protein, and systolic arterial pressure in the Sprague-Dawley control (SD) rats and untreated, low-protein
diet (LPD)–treated and AST-120 (AST)–treated Imai rats at ages 10 weeks and 34 weeks
Imai rat Imai rat LPD Imai rat AST Imai rat
SD rat week 10 week 34 week 34 week 34
T Chol mg/dL 63.72.9 74.02.9 357.019.6a,b 245.717.6a,b,c 224.013.4a,b,c
LDL cholesterol mg/dL 12.33.0 14.63.5 189.412.5a,b 139.911.9a,b,c 122.610.5a,b,c
VLDL cholesterol mg/dL 23.41.5 29.65.1 77.711.2a,b 41.317.4a,b,c 34.68.5a,b,c
HDL cholesterol mg/dL 28.12.2 29.84.3 89.98.2a,b 147.112.3a,b,c 154.89.1a,b,c
TG mg/dL 73.110.2 107.214.4a 218.115.2a,b 169.311.4a,b,c 167.210.4a,b,c
VLDL-TG mg/dL 63.010.2 98.99.2a 194.416.3a,b 155.48.2a,b,c 148.99.2a,b,c
Albumin g/dL 3.70.1 3.50.1 2.80.0a,b 3.30.1c 3.20.1c
Creatinine mg/dL 0.540.29 0.430.01 1.050.14a,b 0.450.02c 0.430.01c
Creatinine clearance/kidney weight
mL/min/g kidney 0.540.03 0.490.14 0.200.04a,b 0.48 0.04c 0.490.03c
Urinary protein/Urinary creatinine 0.390.06 2.8313.6a 29.42.9a,b 13.81.2a,b,c 16.11.3a,b,c
Blood pressure mm Hg 116.75.9 133.68.6 187.612.6a,b 145.012.6a,c 143.610.9a,c
aP  0.05 vs. control; bP  0.05 vs. 10-week-old Imai rats; cP  0.05 vs. untreated 34-week-old Imai rats
reaction. The adjusted data were then used in the calcula-
tion of the LPL and hepatic lipase activities.
Serum and urine measurements
Urinary and serum protein concentrations were mea-
sured by use of the biuret reaction. Serum total choles-
terol was measured by a kit purchased from Boehringer
Mannheim Inc. (Mannheim, Germany). HDL, LDL, and
VLDL were determined by the ultracentrifugation method.
Serum creatinine was assayed using a creatinine analyzer
(Creatinine Analyzer, Beckman Instruments, Brea, CA,
USA).
Western blot analyses
LPL abundance. Lipoprotein lipase protein abun-
dance in the adipose tissue and skeletal muscle was deter-
mined by Western blot analysis as described previously
by Vaziri and Liang [12]. The monoclonal antibody
(5D2) employed in this assay was generously supplied
by Professor John Brunzell (University of Washington,
Seattle, WA, USA). This monoclonal antibody was
raised against purified bovine milk LPL. It recognizes
LPL present in human plasma and in the skeletal muscle,
myocardium, and adipose tissues of rats. This antibody
has been widely used in quantification of rat plasma
and tissue LPL by either enzyme-linked immunosorbent
assay (ELISA) or Western blot techniques.
VLDL receptor protein abundance. VLDL receptor
protein abundance in the skeletal muscle and adipose
tissue was quantified by Western blot analysis in a man-
ner that was identical to that described previously by
Liang and Vaziri [7]. The antibody employed in this
assay was derived from the hybridoma cell line, IgG-
GAG, which produces a monoclonal antibody recogniz-
ing the cytoplasmic domain of VLDL receptor in hu-
mans, rats, and several other species. This antibody was
prepared in our laboratory.
Data analysis
Data are presented as mean  SD. Analysis of vari-
ance (ANOVA) and Duncan’s multiple range tests were
performed in statistical analysis of the data. P values
0.05 were considered significant.
RESULTS
General data
Data are shown in Table l. At the beginning of the
study, 10-week-old Imai rats showed mild proteinuria,
slightly elevated arterial pressure, and normal creatinine
clearance. Mild proteinuria at this stage was coupled
with a mild elevation of plasma triglyceride, VLDL, and
cholesterol levels. With advanced age the untreated 34-
week-old Imai rats exhibited severe proteinuria, hypo-
albuminemia, azotemia, diminished creatinine clearance,
and marked hypertension. This was associated with se-
vere hypercholesterolemia, hypertriglyceridemia, and el-
evation of plasma VLDL and LDL levels. The HDL-
to-LDL cholesterol ratio in the untreated 34-week-old
Imai rats (0.5) was markedly reduced as compared to that
seen in the control group (2.3) and prenephrotic 10-
week-old Imai rats (2.1). Protein restriction and AST-
120 administration significantly improved (but did not
normalize) HDL-to-LDL cholesterol ratio (1.1 and 1.3,
respectively). As expected, dietary protein restriction
resulted in significant attenuation of proteinuria, hypo-
albuminemia, and renal insufficiency. This was associ-
ated with significant improvement of in plasma lipid lev-
els in the protein restricted 34-week-old Imai rats as
compared to those consuming regular diet. Likewise,
administration of AST-120 resulted in significant preser-
vation of renal function, moderate reduction in protein-
uria (less so than LPD), and significant attenuation of
hyperlipidemia and hypertension in the treated animals
as compared with the untreated group.
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Fig. 1. Plasma post-heparin lipoprotein lipase (LPL) (A ) and hepatic
lipase (HL) (B ) activities in Sprague-Dawley control (SD) rats and
untreated [focal glomerulosclerosis (FGS)], low-protein diet (LPD)–
treated and AST-120 (AST)–treated Imai rats with FGS obtained at
age 20 and 34 weeks (N  6 in each group). *P  0.01 vs. control;
P  0.05 vs. FGS group.
Lipoprotein lipase data
Data are shown in Figures 1 to 3. The 34-week-old
Imai rats exhibited severe reduction of skeletal muscle
and adipose tissue LPL protein abundance when com-
pared with the control group. This was accompanied by
a significant reduction in post-heparin LPL activity in
the untreated animals. Both protein restriction and AST-
120 therapy significantly improved (but did not normal-
ize) skeletal muscle and adipose tissue LPL protein
abundance. The effect of these therapies on post-heparin
lipolytic activity was more impressive, suggesting a
greater action on the biologically active endothelial-
bound LPL fraction relative to the inactive intracellular
LPL pool.
Hepatic triglyceride lipase data
Data are shown in Figure 1. The untreated 34-week-
old Imai rats showed severe reduction in hepatic triglyc-
eride lipase activity as compared to the control group.
Both protein restriction and AST-120 therapies im-
proved (but did not normalize) hepatic triglyceride lipase
activity.
Fig. 2. Representative Western blot and group data depicting lipopro-
tein lipase (LPL) protein abundance in skeletal muscle of Sprague-
Dawley control (SD) rats and untreated [focal glomerulosclerosis
(FGS)], low-protein diet (LPD)–treated and AST-120 (AST)–treated
Imai rats with FGS (N  6 in each group). *P  0.01 vs. SD group;
P  0.05 vs. FGS group.
VLDL receptor data
Data are shown in Figures 4 and 5. The untreated 34-
week-old Imai rats showed marked down-regulation of
VLDL receptor in both skeletal muscle and adipose tis-
sues when compared with the corresponding values in
the control group. Administration of LPD and AST-120
resulted in significant but incomplete amelioration of
VLDL receptor expression in the treated animals.
DISCUSSION
At 10 weeks of age, the Imai rats exhibited normal
serum albumin and creatinine concentrations, mild ele-
vations of urinary protein excretion, arterial pressure,
and serum lipid levels. As expected during the ensuing
24-week study period, the untreated Imai rats experi-
enced progressive nephropathy marked by severe hyper-
tension, a tenfold increase in urinary protein excretion,
a more than twofold rise in serum creatinine concentra-
tion, a greater than 50% reduction in creatinine clear-
ance, and a marked decline in serum albumin level. This
was accompanied by a fivefold rise in serum total choles-
terol, and a greater than twofold increase in serum total
triglyceride concentrations.
Dietary protein restriction has been shown to retard
progression of renal disease in chronic renal insufficiency
and to ameliorate proteinuria in nephrotic syndrome
[17–19]. Likewise, administration of oral adsorbent,
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Fig. 3. Representative Western blot and group data depicting lipopro-
tein lipase (LPL) protein abundance in adipose tissue of P  0.01
Sprague-Dawley control (SD) rats and untreated [focal glomeruloscle-
rosis (FGS)], low-protein diet (LPD)–treated and AST-120 (AST)–
treated Imai rats with FGS (N  6 in each group). *P  0.01 vs. SD
group; P  0.05 vs. FGS group.
AST-120, has been reported to delay progression of renal
insufficiency in humans with chronic renal failure [22, 23],
Imai rats with FGS, and rats with 5/6 nephrectomy [20,
21, 24–28]. In fact, long-term administration of this oral
adsorbent has been shown to reduce glomerulosclerosis
and interstitial fibrosis, which represent the common
pathway for proteinuria and progression of renal disease.
Adsorption of uremic toxins or their precursors by AST-
120 prevents their absorption in the gastrointestinal tract
and as such can lower their abundance in the circulation.
For instance, use of this agent has been shown to reduce
the plasma level of indoxyl sulfate [23, 25, 29] and
p-cresol [30]. Uremic toxins are thought to promote glo-
merulosclerosis and interstitial fibrosis by up-regulating
transforming growth factor beta (TGF-). In support of
this concept, Aoyama et al [21, 24] have demonstrated
overabundance of TGF- and osteopontin in kidneys of
untreated 5/6 nephrectomized rats and Imai rats with
glomerulosclerosis and interstitial fibrosis. Administra-
tion of oral adsorbent, AST-120, was shown to attenuate
TGF- and osteopontin expression, as well as glomerular
and interstitial lesions [21, 24]. This was associated with
and largely responsible for amelioration of proteinuria and
renal insufficiency in the treated compared to the un-
treated animals. In view of these considerations, we hy-
pothesized that amelioration of proteinuria and renal
insufficiency with either dietary protein restriction or
Fig. 4. Representative Western blot and group data depicting very
low-density lipoprotein (VLDL) receptor protein abundance in skeletal
muscle of Sprague-Dawley control (SD) rats and untreated [focal glo-
merulosclerosis (FGS)], low-protein diet (LPD)–treated and AST-120
(AST)–treated Imai rats with FGS (N  6 in each group). *P  0.01
vs. SD group; P  0.05 vs. FGS group.
AST-120 administration may improve lipoprotein lipase,
hepatic triglyceride lipase, and VLDL receptor defi-
ciency, and the associated hyperlipidemia in this model.
Both dietary protein restriction and administration of
oral adsorbent, AST-120, prevented the fall in creatinine
clearance and the rise in serum creatinine concentration
in the treated Imai rats. In addition, severity of protein-
uria was reduced by approximately 54% with protein
restriction and 46% with AST-120 administration. Like-
wise, both treatments significantly attenuated the magni-
tude of the associated hyperlipidemia and significantly
increased HDL cholesterol concentration.
Together lipoprotein lipase, hepatic triglyceride lipase,
and VLDL receptor play a central role in metabolism
and clearance of triglyceride-rich lipoproteins. For in-
stance, in presence of Apo C-II, lipoprotein lipase cata-
lyzes hydrolysis of triglycerides in VLDL and chylomi-
crons. This leads to the formation of intermediate density
lipoprotein (IDL) particles and chylomicron remnants
and release of free fatty acids for uptake by the muscle
or adipose tissue. Chylomicron remnants and a small
fraction of IDL particles are subsequently removed by
hepatic remnant receptors. However, the majority of IDL
particles, which are devoid of Apo C-II, undergo further
Sato et al: Hyperlipidemia in focal glomerulosclerosis 1785
Fig. 5. Representative Western blot and group data depicting very
low-density lipoprotein (VLDL) receptor protein abundance in adipose
tissue of Sprague-Dawley control (SD) rats and untreated [focal glomer-
ulosclerosis (FGS)], low-protein diet (LPD)–treated and AST-120
(AST)–treated Imai rats with FGS (N  6 in each group). *P  0.01
vs. SD group; P  0.05 vs. FGS group.
lipolysis by hepatic triglyceride lipase (whose lipolytic
activity is independent of Apo C-II) to become LDL.
Conversion of IDL to LDL also involves acquisition of
cholesterol ester from HDL-2 particles in exchange for
triglycerides via cholesterol ester transfer protein (CETP)
in the circulation.
In addition to the lipolytic pathway outlined above,
VLDL particles can be cleared via the novel VLDL recep-
tor–mediated process [31–33]. Both nephrotic syndrome
and renal insufficiency are known to separately lower lipo-
protein lipase, hepatic lipase, and VLDL receptor abun-
dance [6, 7, 12–14]. Advanced FGS in our untreated Imai
rats was associated with severe nephrotic proteinuria and
moderate renal insufficiency resulting in marked down-
regulations of lipoprotein lipase, hepatic triglyceride li-
pase, and VLDL receptor. These observations are consis-
tent with our earlier findings in this model [3].
Dietary protein restriction and AST-120 administra-
tion resulted in a significant but partial improvement of
skeletal muscle and adipose tissue lipoprotein lipase and
VLDL receptor protein expression in the treated Imai
rats. This was associated with and undoubtedly due to
prevention of renal insufficiency and attenuation of pro-
teinuria by these interventions. The partial preservation
of immunodetectable LPL protein abundance in the
skeletal muscle and adipose tissue of the treated Imai
rats was accompanied by an even greater rise in the
plasma post-heparin lipoprotein lipase activity. This ob-
servation suggests that the given treatments preferen-
tially augment the biologically active, endothelial-bound
fraction relative to the unavailable intracellular pool of
the enzyme.
Both nephrotic syndrome [34] and chronic renal fail-
ure [35] separately cause hepatic triglyceride lipase de-
ficiency. Therefore, combined renal insufficiency and
nephrotic proteinuria can account for the hepatic triglyc-
eride lipase deficiency observed in our untreated Imai
rats with advanced FGS. Once again, partial ameliora-
tion of proteinuria and prevention of renal insufficiency
with dietary protein restriction or AST-120 administra-
tion was accompanied by and most likely responsible for
the observed improvement of hepatic triglyceride lipase
activity in the treated Imai rats. In addition, AST-120
has been shown to trap and prevent reabsorption of
bile acids in the intestine and, thereby, exert a direct
cholesterol-lowering action [36] besides its indirect effect
via amelioration of proteinuria and renal insufficiency.
It is of note that the severe rise in total and LDL
cholesterol concentrations in the 34-week-old Imai rats
was associated with a modest rise in HDL cholesterol
concentration. Due to the lack of CETP in rats [37], HDL
and VLDL serve as the primary carriers of cholesterol in
the circulation while LDL plays a lesser role. Conse-
quently, conditions that give rise to hypercholesterol-
emia are inevitably associated with increased HDL cho-
lesterol in the rat, a phenomenon that has been, in part,
credited with rat’s resistance to atherogenesis. The au-
thors wish to point out that the rise in HDL cholesterol
in the untreated 34-week-old Imai rats was far less than
that of either total or LDL cholesterol concentrations.
This is evidenced by marked reduction of HDL-to-LDL
cholesterol ratio in the severely proteinuric 34-week-old
Imai rat compared with those in prenephrotic 10-week-
old Imai rats and the Sprague-Dawley control rats. The
severe decline of HDL-to-LDL cholesterol ratio in the
untreated Imai rats with advanced FGS is at least, in
part, due to acquired LCAT deficiency recently shown
to occur in this model, as well as in rats with puromycin-
induced nephrotic syndrome and rats with chronic renal
insufficiency [5, 38–39]. In this context, attenuation of
proteinuria and prevention of renal insufficiency can ac-
count for the observed improvement of HDL-to-LDL
cholesterol concentration ratios in Imai rats treated with
protein restriction or AST-120 administration.
CONCLUSION
Long-term dietary protein restriction and administra-
tion of oral adsorbent, AST-120, can slow progression
of renal disease, mitigate severity of the associated hy-
perlipidemia and the underlying lipoprotein lipase, he-
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patic triglyceride lipase, and VLDL receptor deficiencies
in rats with progressive FGS.
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